Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine adjuvant and application thereof and porcine reproductive and respiratory syndrome vaccine

A respiratory syndrome and vaccine adjuvant technology, which is applied in the field of vaccine adjuvants and porcine reproductive and respiratory syndrome vaccines, can solve the problems of shortening the production time of neutralizing antibodies, enhance safety and immunity, and reduce viremia , improve the effect of cellular immunity

Inactive Publication Date: 2019-04-23
龙阔(苏州)生物工程有限公司
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The embodiment of the present invention provides a vaccine adjuvant, aiming to solve the problem of how to enhance the PRRSV vaccine-specific cellular immune response, increase the titer of neutralizing antibodies, shorten the production time of neutralizing antibodies, and enhance the safety of the vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine adjuvant and application thereof and porcine reproductive and respiratory syndrome vaccine
  • Vaccine adjuvant and application thereof and porcine reproductive and respiratory syndrome vaccine
  • Vaccine adjuvant and application thereof and porcine reproductive and respiratory syndrome vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] A vaccine adjuvant comprising the following components: 1 mg of quillaja extract, 2 mg of TLR3 receptor effector (double-stranded RNA), 5 g of diethylaminoethyl glucose and 1 g of stabilizer (phosphate buffered saline).

[0027] The porcine reproductive and respiratory syndrome vaccine of the embodiment of the present invention is prepared by the following steps:

[0028] Weigh each component according to the above-mentioned vaccine adjuvant formula, and set aside;

[0029]Add soap tree extract, TLR3 receptor effector, diethylaminoethyl glucose and stabilizer to inactivated porcine reproductive and respiratory syndrome inactivated antigen solution in sequence, and stir evenly. The pH of the porcine reproductive and respiratory syndrome vaccine was adjusted to 6.8.

Embodiment 2

[0031] A vaccine adjuvant comprising the following components: 10 mg of quillaja extract, 5 mg of TLR3 receptor effector (double-stranded RNA), 2 g of diethylaminoethyl glucose and 3 g of stabilizer (phosphate buffered saline).

[0032] The porcine reproductive and respiratory syndrome vaccine of the embodiment of the present invention is prepared by the following steps:

[0033] Weigh each component according to the above-mentioned vaccine adjuvant formula, and set aside;

[0034] Add soap tree extract, TLR3 receptor effector, diethylaminoethyl glucose and stabilizer to inactivated porcine reproductive and respiratory syndrome inactivated antigen solution in sequence, and stir evenly. The pH of the porcine reproductive and respiratory syndrome vaccine was adjusted to 7.8.

Embodiment 3

[0036] A vaccine adjuvant comprising the following components: 5 mg of quillaja extract, 3 mg of a TLR3 receptor effector (double-stranded RNA), 4 g of diethylaminoethyl glucose and 3 g of a stabilizer (phosphate buffered saline).

[0037] The porcine reproductive and respiratory syndrome vaccine of the embodiment of the present invention is prepared by the following steps:

[0038] Weigh each component according to the above-mentioned vaccine adjuvant formula, and set aside;

[0039] Add soap tree extract, TLR3 receptor effector, diethylaminoethyl glucose and stabilizer to inactivated porcine reproductive and respiratory syndrome inactivated antigen solution in sequence, and stir evenly. The pH of the porcine reproductive and respiratory syndrome vaccine was adjusted to 7.0.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is applicable to the field of biomedicine, and provides a vaccine adjuvant and application thereof and a porcine reproductive and respiratory syndrome vaccine. The vaccine adjuvant is prepared from, by weight, 1-10 parts of a quillaja extract, 2-5 parts of a TLR3 receptor effector, 2000-5000 parts of diethylaminoethyl glucose and 1000-3000 parts of a stabilizer. The vaccine adjuvantis combined with a porcine reproductive and respiratory syndrome virus (PRRSV) inactivated antigen to increase the cellular immunity of a body, induce an interferon and reduce immunosuppression of PRRSV production. Thereof, a high content of a neutralizing antibody is produced more quickly, the maintenance time is long, the viremia of different strains can be reduced, and the safety and immune efficacy of the vaccine are enhanced.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a vaccine adjuvant and its application and a porcine reproductive and respiratory syndrome vaccine. Background technique [0002] Porcine reproductive and respiratory syndrome (PRRS, Porcine Reproductive and Respiratory Syndrome) is a highly contagious disease in pigs. The pathogen is porcine reproductive and respiratory syndrome virus. The main host of the virus is domestic pigs and wild boars in nature. . Pigs of different ages, breeds and genders can be infected with PRRSV (Porcine Reproductive and Respiratory Syndrome Virus), among which pregnant sows and suckling piglets are most likely to be infected. In addition to infecting animals, boar semen has also been identified as a common source of PRRSV infection. [0003] The current common method of preventing and controlling PRRS is immunization and vaccination. Commonly used PRRS vaccines mainly include live attenuat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/12A61P31/14
CPCA61K39/12A61K39/39A61K2039/5252A61K2039/552A61K2039/55511A61K2039/55588A61P31/14C12N2770/10034
Inventor 赖志高俊锋马晶晶韩相敏龙进学吴碧清王杰
Owner 龙阔(苏州)生物工程有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com